Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tamar Ben-Yedidia

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Molecular Immunology|September 11, 2002
A retro-inverso peptide analogue of influenza virus hemagglutinin B-cell epitope 91-108 induces a strong mucosal and systemic immune response and confers protection in mice after intranasal immunizationTamar Ben-Yedidia, Anne-Sophie Beignon, Charalambos D Partidos, et al.
The Journal of Cell Biology|November 19, 2003
Autoregulation of E-cadherin expression by cadherin-cadherin interactions: the roles of beta-catenin signaling, Slug, and MAPKMaralice Conacci-Sorrell, Inbal Simcha, Tamar Ben-Yedidia, et al.
Genes & Development|August 17, 2002
Nr-CAM is a target gene of the beta-catenin/LEF-1 pathway in melanoma and colon cancer and its expression enhances motility and confers tumorigenesisMaralice E Conacci-Sorrell, Tamar Ben-Yedidia, Michael Shtutman, et al.
Journal of Clinical Immunology|February 10, 2012
Safety and immunogenicity of multimeric-001--a novel universal influenza vaccineJacob Atsmon, Efrat Kate-Ilovitz, Dimitry Shaikevich, et al.
Medicine|March 16, 2017
Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine: Phase IIb study protocolEva van Doorn, Heng Liu, Tamar Ben-Yedidia, et al.
Vaccine|September 1, 2014
Priming by a novel universal influenza vaccine (Multimeric-001)-a gateway for improving immune response in the elderly populationJacob Atsmon, Yoseph Caraco, Sagit Ziv-Sefer, et al.
Antiviral Research|December 8, 2023
Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamstersMetin Aksu, Priya Kumar, Thomas Güttler, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Molecular Immunology|September 11, 2002
A retro-inverso peptide analogue of influenza virus hemagglutinin B-cell epitope 91-108 induces a strong mucosal and systemic immune response and confers protection in mice after intranasal immunizationTamar Ben-Yedidia, Anne-Sophie Beignon, Charalambos D Partidos, et al.
The Journal of Cell Biology|November 19, 2003
Autoregulation of E-cadherin expression by cadherin-cadherin interactions: the roles of beta-catenin signaling, Slug, and MAPKMaralice Conacci-Sorrell, Inbal Simcha, Tamar Ben-Yedidia, et al.
Genes & Development|August 17, 2002
Nr-CAM is a target gene of the beta-catenin/LEF-1 pathway in melanoma and colon cancer and its expression enhances motility and confers tumorigenesisMaralice E Conacci-Sorrell, Tamar Ben-Yedidia, Michael Shtutman, et al.
Journal of Clinical Immunology|February 10, 2012
Safety and immunogenicity of multimeric-001--a novel universal influenza vaccineJacob Atsmon, Efrat Kate-Ilovitz, Dimitry Shaikevich, et al.
Medicine|March 16, 2017
Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine: Phase IIb study protocolEva van Doorn, Heng Liu, Tamar Ben-Yedidia, et al.
Vaccine|September 1, 2014
Priming by a novel universal influenza vaccine (Multimeric-001)-a gateway for improving immune response in the elderly populationJacob Atsmon, Yoseph Caraco, Sagit Ziv-Sefer, et al.
Antiviral Research|December 8, 2023
Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamstersMetin Aksu, Priya Kumar, Thomas Güttler, et al.
Pageof 2